Welcome to our dedicated page for Paysign SEC filings (Ticker: PAYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Paysign, Inc. filings document formal disclosures for a Nevada public company providing patient affordability programs, donor compensation solutions, engagement and management platforms, and integrated payment processing. Recent Form 8-K reports furnish operating results and financial-condition updates tied to quarterly and annual earnings releases.
The company’s proxy materials describe annual meeting matters, director elections, auditor ratification, board and committee responsibilities, executive compensation, and beneficial ownership of Paysign securities. Other current reports include Regulation FD disclosures related to stockholder derivative action settlement materials, giving the filing record governance, litigation, ownership and reporting-context coverage in addition to financial results.
Paysign, Inc. has moved toward resolving several previously reported stockholder derivative lawsuits by entering into a Stipulation and Agreement of Settlement as a nominal defendant. The cases, all in the U.S. District Court for the District of Nevada, alleged securities law violations and related fiduciary claims, and are collectively referred to as the Derivative Actions.
On August 28, 2025, the Court set a final approval hearing for November 14, 2025 at 1:00 p.m. to decide whether the proposed settlement is fair, reasonable, and adequate and to consider any objections. If the Court grants final approval, the settlement will release all claims arising from the Derivative Actions, dismiss the cases with prejudice, and require Paysign to adopt and maintain specified corporate governance reforms. The settlement does not include any admission of fault or wrongdoing, and Paysign states that resolving the claims now is in the best interests of the company and its stockholders given the costs and risks of continued litigation.
Key results (Q2 2025): Total revenues $19,078,353; gross profit $11,755,165; net income $1,387,761; gross margin 61.6%.
Six months YTD: Revenues $37,676,502; net income $3,973,861; gross margin 62.2%. Total assets $193,896,201; total liabilities $151,688,242; cash and restricted cash $113,913,123.
Drivers and transactions: Revenue growth driven by pharma industry (+$5,079,005; +189.9% Q2; +$11,309,014; +223.3% YTD). Plasma revenue declined (-4.7% Q2; -6.9% YTD). On March 19, 2025 Paysign acquired Gamma Innovation LLC: preliminary purchase consideration $15,558,637; identifiable intangible assets $11,071,000; goodwill $4,487,637; earn-out contingent consideration revised to $990,000.
Paysign, Inc. (PAYS) – Form 4 insider activity
Chief Legal Officer Robert Strobo reported two transactions. On 31 Jul 2025 he vested/exercised 64,000 restricted shares (Code “M”) at $0, lifting his direct holding to 273,811 shares. On 4 Aug 2025 he sold 26,521 common shares in the open market (Code “S”) at a weighted-average price of $7.0851 (range $6.9976–$7.1530). Post-sale he directly owns 247,290 shares.
The stock grant vests 20 % annually from 31 Jul 2022 through 31 Jul 2027. Derivative table shows 128,000 shares still underlying outstanding awards.
- Net change: +37,479 shares retained.
- Portion sold: ≈41 % of newly vested shares.
No earnings, guidance, or other financial disclosures are included.
Paysign, Inc. (PAYS) Form 4 highlights insider activity by CFO Jeffery B. Baker.
- On 07/31/2025 Baker received 64,000 common shares as part of a previously granted restricted stock award; the grant vests 20 % annually from 07/31/2022 through 07/31/2027 and carried a $0 exercise price.
- On 08/04/2025 he sold 30,396 shares at a weighted-average price of $7.0851 (sales occurred within a price range of $6.9976–$7.1530).
Following these transactions Baker directly owns 252,273 common shares and retains derivative rights to 128,000 additional shares tied to the same award. The filing discloses no new option grants, compensation changes or company-specific events and indicates the sale was executed under a Rule 10b5-1 plan. Overall, the activity appears routine, with the executive maintaining a substantial equity stake.
Paysign, Inc. (PAYS) Form 4: Chief Payments Officer & Director Matthew Lanford reported two transactions. On 31-Jul-2025 he vested and acquired 64,000 common shares at a $0.00 exercise price from a 2022 restricted-stock grant (one-fifth vests annually through 31-Jul-2027). On 04-Aug-2025 he sold 26,367 shares on the open market at a weighted-average $7.0851 (range $6.9976-$7.1530). After these trades he directly owns 147,364 common shares and holds 128,000 unvested/derivative shares under the same grant. The filing was submitted as a single-person report and is not 10b5-1 designated.